BIOMARIN PHARMACEUTICAL INC: Major Acquisition News

BioMarin Pharmaceutical (BMRN) has officially acquired Amicus Therapeutics, marking a major consolidation in the rare disease biotech industry. As of April 27, 2026, Amicus is now a wholly owned subsidiary of BioMarin.

1. What happened?

BioMarin bought Amicus Therapeutics in an all-cash deal worth $4.8 billion. Under the agreement, Amicus shareholders received $14.50 in cash for each share they owned. Amicus is no longer a public company and now operates as a core part of BioMarin.

2. Why did they do it?

BioMarin develops treatments for rare, life-threatening genetic diseases. This deal expands their portfolio by adding several established drugs:

• Galafold® (migalastat): An oral medicine for adults with Fabry disease.
• Pombiliti® and Opfolda®: A two-part therapy for late-onset Pompe disease.
• DMX-200: A drug currently in Phase 3 testing for a rare, fatal kidney disease.

BioMarin plans to use its global sales and manufacturing reach to help more patients access these treatments than Amicus could reach on its own.

3. How did they pay for it?

BioMarin funded the $4.8 billion price tag using its own cash and a new $3.4 billion loan package. This debt includes:

• $2.8 billion in term loans: These are secured loans that must be paid back with interest over the next five to seven years.
• $600 million in a revolving credit facility: This acts as a flexible line of credit for day-to-day business needs.

4. Why does this matter?

This move shifts BioMarin toward a larger, more diverse business model, but it also adds significant debt to their balance sheet.

• The Upside: Adding Galafold and the Pombiliti/Opfolda regimen creates more steady sales. This could stabilize cash flow and strengthen BioMarin’s position in the rare disease market.
• The Risk: The $3.4 billion in new debt increases interest costs and financial pressure. The loan agreement includes strict rules that limit how BioMarin spends money, borrows more, or sells assets. If the company fails to integrate these new products or misses financial targets, its cash reserves could be strained.

5. What should you watch for next?

• Earnings Call (May 4, 2026): Management will update their financial outlook for 2026. Look for details on how debt payments will affect profit and how the new revenue compares to the costs of the deal.
• Integration: Watch how well BioMarin combines research and sales teams without disrupting the supply of Galafold and Pombiliti. Look for updates on cost savings and operational changes.
• Volatility: Investors are still deciding if the $4.8 billion price was worth the long-term growth. Expect the stock price to swing as the market watches how BioMarin manages its new debt while keeping its research pipeline on track.

Investor Tip: Before making any decisions, pay close attention to the May 4th earnings call. Specifically, listen for management’s commentary on "synergies"—this is industry speak for how much money they expect to save by combining the two companies. If they can prove that the cost savings will cover the interest on that $3.4 billion debt, it’s a strong sign for the company's long-term health.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and shouldn't be taken as professional investment advice. Always do your own research before making any trades!